|Mr. George Jay Goldsmith||Co-Founder, Chairman & CEO||722.79k||N/A||1954|
|Dr. Ekaterina Malievskaia M.D.||Co-Founder, Chief Innovation Officer & Exec. Director||536.4k||N/A||1967|
|Mr. Lars Christian Wilde||Sr. Advisor||N/A||N/A||1986|
|Mr. Michael F. Falvey||Chief Financial Officer||N/A||N/A||1959|
|Dr. Greg Ryslik Ph.D.||Exec. VP of AI, Engineering, Digital Health Research & Technology||N/A||N/A||N/A|
|Mr. Stephen D. Schultz||Sr. VP of Investor Relations||N/A||N/A||N/A|
|Mr. Matthew Owens||Gen. Counsel & Chief Legal Officer||N/A||N/A||N/A|
|Ms. Tracy Cheung||Chief Communications Officer||N/A||N/A||N/A|
|Ms. Anne Benedict||Chief People Officer||N/A||N/A||N/A|
|Mr. Marco Mohwinckel||Chief Commercial Officer||N/A||N/A||N/A|
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
COMPASS Pathways plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.